Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Daiichi Sankyo Co Ltd – Key Facts 6
Daiichi Sankyo Co Ltd – Key Employees 7
Daiichi Sankyo Co Ltd – Key Employee Biographies 8
Daiichi Sankyo Co Ltd – Major Products and Services 9
Daiichi Sankyo Co Ltd – History 10
Daiichi Sankyo Co Ltd – Company Statement 21
Daiichi Sankyo Co Ltd – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Joint Venture 25
Section 2 – Company Analysis 26
Company Overview 26
Daiichi Sankyo Co Ltd – Business Description 27
Product Category: Generic Business 27
Overview 27
Performance 27
Product Category: Innovative Pharmaceuticals Business 27
Overview 27
Performance 28
Product Category: OTC Related Business 28
Overview 28
Performance 28
Product Category: Others 28
Performance 28
Performance 28
Product Category: Vaccine Business 29
Overview 29
Performance 29
Product Category: Healthcare (OTC) Products 29
Overview 29
Performance 29
Product Category: Others 29
Performance 29
Performance 29
Product Category: Prescription drugs 30
Overview 30
Performance 30
Geographical Segment: Europe 30
Performance 30
Geographical Segment: Japan 30
Performance 30
Geographical Segment: North America 30
Performance 30
Geographical Segment: Other Regions 30
Performance 30
R&D Overview 30
Daiichi Sankyo Co Ltd – Corporate Strategy 32
Daiichi Sankyo Co Ltd – SWOT Analysis 33
SWOT Analysis – Overview 33
Daiichi Sankyo Co Ltd – Strengths 33
Daiichi Sankyo Co Ltd – Weaknesses 34
Daiichi Sankyo Co Ltd – Opportunities 35
Daiichi Sankyo Co Ltd – Threats 36
Daiichi Sankyo Co Ltd – Key Competitors 37
Section 3 – Company Financial Ratios 38
Financial Ratios – Capital Market Ratios 38
Financial Ratios – Annual Ratios 39
Performance Chart 42
Financial Performance 42
Financial Ratios – Interim Ratios 43
Financial Ratios – Ratio Charts 44
Section 4 – Company’s Lifesciences Financial Deals and Alliances 45
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 45
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 46
Daiichi Sankyo Co Ltd, Recent Deals Summary 47
Section 5 – Company’s Recent Developments 48
Oct 09, 2018: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo announce second public recruitment offering of “Joinus”, a joint research program to discover new drugs using drug-repositioning compound library 48
Sep 24, 2018: Daiichi Sankyo Presents Updated Results for Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Mutated or HER2 Expressing Non-Small Cell Lung Cancer at IASLC 19th World Conference on Lung Cancer 49
Sep 24, 2018: Daiichi Sankyo Presents Updated Results for Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Mutated or HER2 Expressing Non-Small Cell Lung Cancer at IASLC 19th World Conference on Lung Cancer 51
Sep 21, 2018: Daiichi Sankyo forms collaboration for Phase lb trial of DS-8201 53
Sep 21, 2018: Daiichi Sankyo forms collaboration for Phase lb trial of DS-8201 54
Sep 11, 2018: TOPC : Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-8201 in Combination with KEYTRUDA® (pembrolizumab) in HER2 Expressing Breast and HER2 Expressing or HER2 Mutant Lung Cancers[Newswire : Healthcare - PRN] 55
Sep 11, 2018: TOPC : Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-8201 in Combination with KEYTRUDA® (pembrolizumab) in HER2 Expressing Breast and HER2 Expressing or HER2 Mutant Lung Cancers[Newswire : Healthcare - PRN] 56
Sep 11, 2018: TOPC : Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-8201 in Combination with KEYTRUDA® (pembrolizumab) in HER2 Expressing Breast and HER2 Expressing or HER2 Mutant Lung Cancers[Newswire : Healthcare - PRN] 57
Aug 29, 2018: ProLynx and Daiichi Sankyo announce the development of technology for half-life extension of small molecules in the eye 58
Aug 28, 2018: Daiichi Sankyo Presents First Snapshot Analyses from Global ETNA-AF Programme of Oral, Once-daily LIXIANA (edoxaban) in Patients with Nonvalvular Atrial Fibrillation in Routine Clinical Practice 59
Section 6 – Appendix 60
Methodology 60
Ratio Definitions 60
About GlobalData 64
Contact Us 64
Disclaimer 64
Daiichi Sankyo Co Ltd, Key Facts 6
Daiichi Sankyo Co Ltd, Key Employees 7
Daiichi Sankyo Co Ltd, Key Employee Biographies 8
Daiichi Sankyo Co Ltd, Major Products and Services 9
Daiichi Sankyo Co Ltd, History 10
Daiichi Sankyo Co Ltd, Subsidiaries 22
Daiichi Sankyo Co Ltd, Joint Venture 25
Daiichi Sankyo Co Ltd, Key Competitors 37
Daiichi Sankyo Co Ltd, Ratios based on current share price 38
Daiichi Sankyo Co Ltd, Annual Ratios 39
Daiichi Sankyo Co Ltd, Annual Ratios (Cont...1) 40
Daiichi Sankyo Co Ltd, Annual Ratios (Cont...2) 41
Daiichi Sankyo Co Ltd, Interim Ratios 43
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 45
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 46
Daiichi Sankyo Co Ltd, Recent Deals Summary 47
Currency Codes 60
Capital Market Ratios 60
Equity Ratios 61
Profitability Ratios 61
Cost Ratios 62
Liquidity Ratios 62
Leverage Ratios 63
Efficiency Ratios 63
List of Figures
Daiichi Sankyo Co Ltd, Performance Chart (2014 - 2018) 42
Daiichi Sankyo Co Ltd, Ratio Charts 44
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 45
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 46
【免責事項】
http://www.globalresearch.jp/disclaimer